As part of the UK-French summit held in Sandhurst yesterday (18 January 2018), the UK and French Governments have announced enhanced cooperation between Genomics England and the French ‘Médecine Génomique 2025’ project.
The Strategic Genomic Medicine Partnership marks a strengthening of the existing relationship between Genomics England and the French National Institute of Health and Medical Research (Inserm). Formalising the agreement, senior representatives of both organisations signed a letter of intent for a Memorandum of Understanding (MoU).
The UK and France will combine our shared national attributes by co-funding shared analysis of new technologies to accelerate genomic medicine and research collaboration, ultimately improving the care of patients with cancer and rare diseases.
The Strategic Partnership announced today sees two global pioneers combining know-how to realise the full potential of genomic medicine. Genomics England and Inserm will work together more closely than ever before – signalling our joint ambition to lead the world in genomic discovery, develop more effective treatments and drive economic growth in the sector.
Sir John Chisholm
Genomics England Executive Chairman
Today’s agreement ensures that the UK and France continue to set the pace in global genomics. Both of our nations are on the verge of introducing genomic medicine into mainstream health services and this enhanced cooperation will allow us to set new and lasting global standards, share learning and, ultimately, deliver the best possible care to our patients.
Professor Mark Caulfield
Genomics England Chief Scientist
Communications & PR